Abstracts tagged "Mortality"

Abstract Number: 0467 • ACR Convergence 2022
All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study
Jacob Sode¹, Jens Rathmann¹, Anna Wilding², Carl Turesson³ and Aladdin Mohammad¹, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden
Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an…
Abstract Number: 1465 • ACR Convergence 2022
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
Vineeta Shobha¹, Liza Rajasekhar², Sandra Manuel¹, Chengappa Kavadichanda³, Ashish J Mathew⁴, Ranjan Gupta⁵, Manish Rathi⁶, Parasar Ghosh⁷, Saumya Ranjan Tripathy⁸, Avinash Jain⁹ and Amita Aggarwal¹⁰, ¹St. John’s Medical College Hospital, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³JIPMER, Pondicherry, Puducherry, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵All India Institute of Medical Sciences, New Delhi, India, ⁶PGIMER Chandigarh, Chandigarh, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Antiphospholipid Antibody (aPL) are described in 11-40% of patients with SLE. Whether the presence of any of the aPLs or combinations thereof, can accurately…
Abstract Number: 2248 • ACR Convergence 2022
Prevalence and Mortality of Interstitial Lung Abnormalities in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort
Gregory McDermott¹, Keigo Hayashi², Kazuki Yoshida¹, Matthew Moll¹, Michael Cho¹, Tracy Doyle¹, Paul Dellaripa¹, Rachel Putman¹, Raul San Jose Estepar¹, George Washko¹, Elizabeth Regan³, Hiroto Hatabu¹, Gary M Hunninghake¹, Edwin Silverman¹ and Jeffrey Sparks⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ³National Jewish Health, Denver, CO, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Subpleural interstitial lung abnormalities (ILA) may be a form of subclinical or preclinical interstitial lung disease (ILD) and have been reported in up to…
Abstract Number: 0539 • ACR Convergence 2022
Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use
Anna Broder¹, Wenzhu B. Mowrey², Kazuki Yoshida³ and Karen Costenbader³, ¹Hackensack University Medical Center, Hackensack, NJ, ²Albert Einstein College of Medicine, Bronx, NY, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Medication management strategies in patients with lupus-related end stage kidney disease (ESKD) have not been studied. Our prior work has shown that HCQ may…
Abstract Number: 1535 • ACR Convergence 2022
Frequency of Arrhythmias, Abnormal Electrocardiography and Sudden Cardiac Death in Systemic Sclerosis: A Systematic Review and Meta-analysis
Jessica Fairley¹, Laura Ross², Alannah Quinlivan³, Dylan Hansen⁴, Elizabeth Paratz⁵, Wendy Stevens⁴, Peter M Kistler⁶, Andre La Gerche⁷ and Mandana Nikpour⁸, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ³St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, ⁴St Vincent's Hospital Melbourne, Melbourne, Australia, ⁵The Baker Institute; St Vincent's Hospital Melbourne, Melbourne, Australia, ⁶The Baker Heart and Diabetes Institute; The University of Melbourne; Monash University, Melbourne, Australia, ⁷The Baker Heart and Diabetes Institute; The University of Melbourne, Melbourne, Australia, ⁸The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Scleroderma (SSc) Heart Involvement (SHI) is an under recognised complication of SSc and may manifest as arrhythmias or sudden cardiac death(SCD). The incidence of…
Abstract Number: 0675 • ACR Convergence 2022
Clinical Characteristics and Factors Associated with Relapse and Mortality in Diffuse Alveolar Hemorrhage Among Patients with Antiphospholipid Syndrome: A Multi-Center Retrospective Cohort
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Hannah Langenfeld², Rodrigo Cartin-Ceba¹, Ulrich Specks¹, Cynthia Crowson³ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN
Background/Purpose: Antiphospholipid syndrome (APS) is associated with diffuse alveolar hemorrhage (DAH). However, only case reports and small case series are available in the literature. We…
Abstract Number: 1650 • ACR Convergence 2022
Systemic Immune Inflammation Index Predict All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose felix Restrepo Suarez¹, Inmaculada Del Rincon¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science center at San Antonio, San Antonio, TX, ²University of Texas Health Sciences Center San Antonio, San antonio, TX, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: The systemic immune inflammation index (SII) is an inflammation-based biomarker that is an influential prognostic factor in diseases with an inflammation-related etiology. This index…
Abstract Number: 0676 • ACR Convergence 2022
Presentation and Outcomes in Patients with Adrenal Hemorrhage Associated with Antiphospholipid Syndrome: A Cohort Study and Systematic Review of Literature
Jose A Meade-Aguilar¹, Gabriel Figueroa Parra¹, Jeffrey X. Yang¹, Hannah Langenfeld², Prerna Dogra¹, Irina Bancos³, Hassan Murad³, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: To describe the clinical characteristics, therapies, and outcomes of patients with antiphospholipid syndrome (APS) and adrenal hemorrhage (AH).Methods: We performed a multicenter retrospective cohort…
Abstract Number: 1660 • ACR Convergence 2022
Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality
Julie Paik¹, Caoilfhionn Connolly¹, Fredrick Wigley¹ and Laura Hummers², ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Univerisity, Baltimore, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is poorly understood. The etiology of myopathy in SSc is heterogeneous and can result from an inflammation, disuse,…
Abstract Number: 0696 • ACR Convergence 2022
The Mortality Trends Related to SLE in the United States – A 20-year Analysis (2001-to 2020) from the WONDER Database
Ikwinder Preet Kaur¹, Harjot Jagdey², hasan Mirza³, Waqar Mughal⁴ and Pankaj Bansal⁵, ¹Rutgers/Monmouth Medical Center, Long branch, NJ, ²BronxCare Hospital, Bronx, NY, ³Berkshire Medical Center, Pittsfield, MA, ⁴DHQ teaching hospital, Gujrat, Pakistan, ⁵Mayo Clinic, Eau Claire, WI
Background/Purpose: SLE is an autoimmune rheumatic disease that contributes to increased morbidity and mortality due to multi-organ involvement, infections, and accelerated atherosclerosis leading to cardiovascular…
Abstract Number: 1667 • ACR Convergence 2022
Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibitors for Cancer Treatment: A Comparative Cohort Study Investigating RA Flare and Mortality
Kaitlin McCarter¹, Taylor Wolfgang¹, Senada Arabelovic¹, Xiaosong Wang¹, Kazuki Yoshida¹, Emily Banasiak¹, Grace Qian¹, Emily Kowalski¹, Kathleen Vanni¹, Nicole LeBoeuf¹, Elizabeth Buchbinder¹, Lydia Gedmintas¹, Lindsey MacFarlane¹, Deepak Rao¹, Nancy Shadick¹, Ellen Gravallese² and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: For patients with pre-existing RA, immune checkpoint inhibitors (ICIs) for cancer treatment may trigger RA flares or other immune-related adverse events. Underlying altered immunity…
Abstract Number: 0454 • ACR Convergence 2021
Lupus Nephritis Mortality in the United States, 1999-2019: Profound Disparities by Race/Ethnicity and Place of Residence and a Recent Worsening Trend
Eric Yen¹, Snehin Rajkumar¹, Rohan Sharma¹ and Ram Singh², ¹University of California Los Angeles, Los Angeles, CA, ²University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Mortality from SLE has improved over the last two decades, but remains disproportionately high relative to general population mortality. Lupus nephritis (LN) occurs in…
Abstract Number: 1047 • ACR Convergence 2021
Exposure to Industrial Pollutants and Mortality Due to Inmune-mediated Inflammatory Systemic Diseases (IMD) in Spain
ana Perez¹, Arturo Rodriguez Pérez², Pablo Fernandez-Navarro³, Fernando Albarran⁴, Cristina Bohorquez⁴, Atusa Movasat⁴, Lucia Ruiz⁴, Paula Pretel⁴, elena Rabadan⁴, Valentina Emperiale⁴, Adrian abbasi⁵, julio suarez⁵, Lorena Montano⁴, emilio rico⁵, alfredo prieto², melchor Alvarez de Mon⁵ and beatriz perez³, ¹Hospital Universitario Príncipe de Asturias. Rheumatology. Medicine Faculty. Alcala University Department., Madrid, Spain, ²Faculty of Medicine. Alcala University, Alcala de Henares, Spain, ³Department of Epidemiology of Chronic Diseases.National Center of Epidemiology/CIBERESP. Instituto de Salud Carlos III, Madrid, Spain, ⁴Hospital Universitario Príncipe de Asturias, Rheumatology Department, Alcala de Henares, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain
Background/Purpose: The etiology of many IMD is largely unknown; however, available data suggest that environmental contaminants could play a role in their origin. Industrial facilities…
Abstract Number: 1899 • ACR Convergence 2021
Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study
Lindsay Helget¹, Bryant England¹, Punyasha Roul¹, Harlan Sayles¹, Alison Petro¹, Tuhina Neogi² and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…
Abstract Number: 0569 • ACR Convergence 2021
All-Cause and Cause-Specific Mortality in Spondyloarthritis: A Systematic Review and Meta-Analysis
Haseeb Chaudhary¹, Nidrit Bohra², Khezar Syed², Anthony Donato², M.Hassan Murad³ and Paras Karmacharya⁴, ¹Tower Health System, Reading, PA, ²Reading Hospital, Tower Health System, Reading, PA, ³Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Mayo Clinic, Rochester, MN Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Spondyloarthritides (SpA) represent a group of chronic inflammatory diseases associated with a higher risk of cardio-metabolic comorbidities compared to the general population. It is…